Login / Signup

Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7-59 months. A matched case-control study.

Ángela DomínguezPilar CiruelaSergi HernándezJuan José García-GarcíaNúria SoldevilaConchita IzquierdoFernando Moraga-LlopAlvaro DíazMariona F de SevillaSebastià González-PerisMagda CampinsSonia UrionaJohanna Martínez-OsorioAnna Solé-RibaltaGemma CodinaCristina EstevaAna María PlanesCarmen Muñoz-AlmagroLuis Salleras
Published in: PloS one (2017)
The effectiveness of ≥1 doses of PCV13 in preventing IPD caused by all PCV13 serotypes in children aged 7-59 months was good and, except for serotype 3, the effectiveness of ≥1 doses against the most frequent PCV13 serotypes causing IPD was high when considered individually.
Keyphrases
  • randomized controlled trial
  • systematic review
  • cancer therapy
  • escherichia coli
  • zika virus
  • drug delivery